Advertisement

Topics

Eisai, with Oncology Group H3 Biomedicine, Doubles Down on Boston

06:00 EST 14 Feb 2011 |

H3 Biomedicine is one of the latest experiments that hopes to revamp the way biotech drugs get developed, to save both time and money. Japanese drugmaker Eisai, which is bankrolling Cambridge, MA-based H3, is betting that a combination of $200 million in cash, access to scientific luminaries, and the support of Eisai’s global research and [...]

Original Article: Eisai, with Oncology Group H3 Biomedicine, Doubles Down on Boston

NEXT ARTICLE

More From BioPortfolio on "Eisai, with Oncology Group H3 Biomedicine, Doubles Down on Boston"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Biotechnology - Biotech
"using living things to create products or to do tasks for humans" About Biotechnology - Biotech Biotechnology is the practice of using plants, animals and micro-organisms such as bacteria, as well as biological processes - such as the ripen...